COVID-19 vaccine sales push Moderna past expectations in Q2
AP – Better-than-expected COVID-19 vaccine sales pushed Moderna past Wall Street’s second-quarter forecasts. The company said that its Spikevax vaccine brought in USD4.53 billion during the quarter. Analysts were looking for around USD3.6 billion, according to FactSet. Moderna shares surged on Wednesday after the company also announced another USD3 billion share buyback plan. Moderna’s vaccine […]
Source: borneobulletin.com.bn